▎藥明康德

編者按：在今年的歐洲產業大會——BayOConnect年會上，藥明康德德國慕尼黑基地負責人Thomas Meins博士在專題對話中探討了CRDMO模式在創新生態圈中的關鍵作用。在深入剖析慕尼黑生物技術生態系統的同時，他也介紹了像藥明康德這樣的全球合作伙伴如何賦能當地乃至全球客戶，讓這一生態系統更具創新活力。本文內容基于德國媒體Tagesspiegel的報道，點擊“閱讀全文/Read more”即可訪問原文頁面。

慕尼黑：蓄勢良久，正待騰飛

慕尼黑擁有得天獨厚的創新條件。該地區有著高度集中的學術資源，匯集了慕尼黑大學（LMU）、慕尼黑工業大學（TUM）、亥姆霍茲研究中心（Helmholtz Munich）、弗勞恩霍夫協會（Fraunhofer）以及馬克斯·普朗克研究所（Max Planck Institutes）等國際一流科研機構，兼具科研深度與全球影響力。

此外，當地生物技術初創企業不斷涌現，投資規模也在迅速擴大。像BayOConnect主辦方BioM這樣的專業組織，致力于為創業者提供有力支持，進一步強化了本地生態體系。

“2024年，德國生物技術初創企業共獲得約10億歐元風險投資，較前一年翻了一番，”Thomas Meins博士引用了BioM的2024/25年度報告中的數據，“其中大部分資金流入了大慕尼黑地區。這說明該地區的生態系統已經準備好邁入下一階段。”

在科學和資金的助力下，慕尼黑生物醫藥生態圈已順利完成了從初見規模到成熟生態的演變：目前，該地區匯聚了超過520家生物技術和醫藥公司，擁有高度集成的服務機構網絡，成為歐洲最具活力的生物技術中心之一。

然而縱觀新興創新中心的成長歷程，不難發現它們的發展往往并非線性，而是會在多年的基礎積累之后，突然實現飛躍。對于慕尼黑而言，接下來的關鍵在于如何將科研實力、企業專長與資本投入，轉化為可衡量的市場價值與創新成果，真正進入下一個騰飛階段。

知名生物醫藥中心的共性

無論是美國的波士頓、舊金山、圣地亞哥，還是英國劍橋等國際知名生物醫藥中心，都具備一些共同特征：它們不僅擁有卓越的科研能力和活躍的投資環境，更離不開強大的綜合服務體系。而在這些體系中，CRDMO組織扮演著不可或缺的角色。

“CRDMO是高效生態系統的關鍵組成部分之一，”Meins博士表示，“它能讓初創企業利用行業已經建立的成熟研發和生產體系，而無需從一開始就投入大量資金。”

不僅是服務提供者，更是創新賦能者

藥明康德擁有獨特的CRDMO模式。該模式的核心理念強調：研究（R）、開發（D）與生產（M）并非彼此割裂，而是融合為一體化服務平臺。從而實現從實驗室到臨床應用的無縫銜接，并涵蓋法規咨詢、技術平臺與全球化產能等多方面支持。

“我們不僅是服務提供者，更是創新賦能者，”Meins博士強調，“我們的使命是幫助客戶更快、更安全、更成功地將產品推向市場，同時為投資者提供他們需要的規模和規劃確定性。”

CRDMO模式降低了開發風險，縮短了產品上市周期，并增強了初創企業對投資者的吸引力。因此，它不僅在技術層面，也在經濟層面直接推動生物技術創新的成功。

「歐洲醫藥高地」的長遠布局

早在2016年，藥明康德便通過收購專注于生物物理和基于結構的藥物發現的Crelux公司，展現了對慕尼黑地區的堅定信心。如今，這一已有近20年歷史的慕尼黑基地，專注于早期藥物發現，重點深耕晶體學、蛋白生物化學與生物物理等領域。

與此同時，藥明康德持續為行業合作伙伴提供高質量服務。今年，慕尼黑基地順利通過德國聯邦藥品和醫療器械管理局（BfArM）的GMP檢查，并獲得歐盟生產/進口許可證（MIA）與GMP認證。這一里程碑標志著公司正式啟動面向歐盟市場的產品批次放行服務（Qualified Person，簡稱QP），能夠為面向歐盟的生物技術公司簡化進口流程，加快藥物惠及患者的速度。

作為藥明康德全球CRDMO網絡中專注于研究（R）的關鍵節點，慕尼黑的科研專長與其他基地的開發（D）和生產（M）能力形成互補。例如，藥明康德化學業務平臺在瑞士的庫威（Couvet）基地正在擴建新的生產設施。2025年5月，該基地啟動全新噴霧干燥制備固體分散體（SDD）車間建設，預計將于2026年第四季度投入運營。該設施將有助于提升低水溶性化合物的生物利用度。通過整合慕尼黑基地的發現能力、瑞士基地的生產能力，以及全球一體化服務網絡，藥明康德為歐洲生物技術企業提供更快速的產品上市路徑，從而助力本地創新能力的提升。

“藥明康德已經深度融入慕尼黑的科研生態多年。我們在全球持續拓展的同時，也在本地不斷加大投入。”Meins博士強調，“我們希望吸引更多生物技術企業與我們攜手合作，共同增強區域生態系統的活力。”

展望：下一輪騰飛的關鍵

“我們需要新一代生物技術公司，它們不僅要實現快速增長，還要具備長期戰略，專注于可持續發展、穩健的產品管線以及國際化拓展。”Meins博士指出，“這需要一個能夠支持這些愿景的生態體系，包括覆蓋各階段的資本支持、現代化基礎設施、法規專業能力與可信賴的合作伙伴。”

目前，藥明康德的活躍客戶數約6000家，涵蓋初創企業及全球大型醫藥公司，是生物醫藥行業重要的一體化服務平臺之一，也是推動區域創新生態發展的重要力量。

展望未來，藥明康德希望與當地及全球的合作伙伴一道，繼續推動這一進程，加速慕尼黑地區的產業騰飛。我們也期待通過加強與創業者、科學家及投資人的持續合作，以及對歐洲基地的不斷升級擴建，以全方位行動踐行承諾，早日實現“讓天下沒有難做的藥，難治的病”的愿景。

Model Region Munich: With companies like WuXi AppTec, Munich is becoming Europe’s leading biotech hub

Dr. Thomas Meins, head of WuXi AppTec’s Munich site, spoke at this year’s BayOConnect about the role of CRDMOs and how to align scientific vision with investor interests. A good reason to take a closer look at the growth dynamics of the Munich ecosystem and how global partners like WuXi AppTec are supporting this process.

Where does Munich stand on the biotech success curve?

The growth of emerging innovation hubs rarely follows a linear path — it often takes years of groundwork before a region truly takes off. Munich has successfully completed this maturing process in recent years: with over 520 biotechnology and pharmaceutical companies and a dense network of service providers, the region is now one of the most dynamic biotech hubs in Europe. The big question is: when will the actual growth phase begin — the moment when scientific strength, entrepreneurial expertise, and capital inflow translate into measurable market and innovation growth?

Many refer to this as the ‘hockey-stick growth’ — a sudden surge following a longer preparatory phase.

The conditions could hardly be better: Munich impresses with an exceptional density of academic excellence. Institutions such as LMU, TUM, Helmholtz Munich, Fraunhofer, and the Max Planck Institutes stand for top-tier research and international appeal.

Added to this is a growing number of ambitious biotech start-ups and sharply increasing investments. This development is supported by specialized cluster initiatives like BioM, the organizer of BayOConnect, which provides targeted support to founders.

“German biotech start-ups raised around 1 billion euros in venture capital in 2024, twice as much as the previous year,” quotes Dr. Thomas Meins from the BioM Annual Report 2024/25. “A large part of this flowed into the Greater Munich area. That shows: the ecosystem is ready for the next step.”

What distinguishes successful biotech hubs?

Looking at internationally successful biotech centers like Boston, San Francisco, Cambridge (UK), or San Diego reveals common features: not only excellent research and an active investor environment, but also powerful, integrated service structures. Contract Research, Development, and Manufacturing Organizations (CRDMOs) play a central role.

“CRDMOs are a crucial component of functioning ecosystems,” says Dr. Meins. “They give young companies access to industrially established research, development, and manufacturing structures without having to make massive investments from the outset.”

The CRDMO model: Enabler rather than mere service provider

WuXi AppTec has been a key driver of the CRDMO model. The idea: research (“R”), development (“D”), and manufacturing (“M”) are not offered in isolation, but combined in an integrated service model. The result is a seamless transition from the laboratory to clinical application, including regulatory advice, technology platforms, and global production capacities.

“We see ourselves not just as a service provider but as an enabler of innovation,” emphasizes Dr. Meins. “Our mission is to help our customers reach the market faster, more safely, and more successfully, while offering investors the scalability and planning certainty they need.”

The CRDMO approach reduces development risks, shortens time-to-market, and makes young companies more attractive to investors. In this way, it contributes directly to the success of biotech innovations — not only technologically, but also economically.

Munich as a strategic location

As early as 2016, WuXi AppTec showed its confidence in the Munich location by acquiring the drug discovery service provider Crelux, a specialist in biophysical and structure-based drug discovery. Today, the Munich site, established nearly 20 years ago, has been expanded and focuses on early-stage drug discovery, particularly in crystallography, protein biochemistry, and biophysics.

Equally important is the high quality that WuXi AppTec delivers to the industry. This year, WuXi AppTec’s Munich site successfully passed the GMP inspection by the BfArM and received the Manufacturing/Import Authorization (MIA) as well as EU-GMP certification. This milestone marks the official launch of WuXi AppTec’s EU release services, also known as Qualified Person (QP) services. This enables simplified import for biotech companies with EU-oriented programs and shortens the time to patient access.

As the “R” site (research) in WuXi AppTec’s global CRDMO network, Munich’s research expertise complements the strengths in “D” (development) and “M” (manufacturing) of other sister sites — such as the expanding production facility in Switzerland.

In May 2025, ground was broken for a new spray dried dispersion (SDD) manufacturing building at the Couvet site in Switzerland. Operations are expected to start in the fourth quarter of 2026. The facility will help improve the bioavailability of poorly water-soluble compounds. By combining Munich’s discovery expertise with Switzerland’s production capacity and all other required capabilities, WuXi AppTec offers European biotech companies faster market access, thereby strengthening local innovation capacity.

“WuXi AppTec has been firmly anchored in Munich’s research landscape for many years. We have been expanding our expertise worldwide for years while continuing to grow locally,” says Dr. Thomas Meins. “Today, we want to attract more biotech companies into our orbit and jointly contribute to the strength of the ecosystem.”

With around 6,000 active customers worldwide, ranging from small start-ups and stealth-mode companies to the top 20 pharma companies, WuXi AppTec is one of the leading end-to-end service providers in the biopharma industry and an active shaper of regional innovation landscapes.

Outlook: How can Munich achieve its next growth spurt?

“We need a new generation of biotech companies that, in addition to rapid growth, also pursue long-term strategies — with a clear focus on sustainable development, robust pipelines, and internationalization,” says Dr. Meins. “This requires an ecosystem that supports these ambitions — with capital for all growth phases, modern infrastructure, regulatory expertise, and reliable partnerships.”

WuXi AppTec aims not just to participate in this process, but to actively lead it. Its presence at BayOConnect, its ongoing collaboration with founders, universities, and investors, and the further development of its Munich site all reflect this ambition.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。